Lyell Immunopharma, Inc.
LYEL • NASDAQ
Lyell Immunopharma, Inc. is a biotechnology company in the healthcare sector trading on NASDAQ, led by CEO Lynn Seely, with a market cap of $458.5M.
CEOLynn Seely
Next Earnings
Upcoming earnings announcement for Lyell Immunopharma, Inc.
Date
Tuesday, May 12, 2026 (in a month)
Timing
After Market Close (4:00 PM New York)
Fiscal Period
Q1 2026
EPS Estimate
-$2.22
Revenue Estimate
$4.0K
Earnings History
Past 12 earnings reports for Lyell Immunopharma, Inc.
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Mar 12, 2026 | Q4 2025 | -$7.68Est: -$2.20 | -249.1% | $6.0KEst: $20.3K | -70.5% | — |
| Nov 12, 2025 | Q3 2025 | -$2.13Est: -$2.71 | +21.4% | $15.0K | — |  10-Q |
| Aug 12, 2025 | Q2 2025 | -$2.89Est: -$2.90 | +0.3% | $8.0K | — | 10-Q |
| May 13, 2025 | Q1 2025 | -$0.18 | — | $7.0K | — | 10-Q |
| Mar 11, 2025 | Q4 2024 | -$0.16Est: -$0.13 | -23.1% | $11.0K | — | 10-K |
| Nov 7, 2024 | Q3 2024 | -$0.14Est: -$0.20 | +30.0% | $34.0K | — | 10-Q |
| Aug 7, 2024 | Q2 2024 | -$0.15Est: -$0.20 | +25.0% | $13.0K | — | 10-Q |
| May 6, 2024 | Q1 2024 | -$0.15Est: -$0.21 | +28.6% | $3.0K | — | 10-Q |
| Feb 28, 2024 | Q4 2023 | -$0.17Est: -$0.23 | +26.1% | $13.0K | — | 10-K |
| Nov 7, 2023 | Q3 2023 | -$0.17Est: -$0.25 | +32.0% | $25.0K | — | — |
| Aug 8, 2023 | Q2 2023 | -$0.04Est: -$0.23 | +82.6% | $27.0K | — | 10-Q |
| May 4, 2023 | Q1 2023 | -$0.18 | — | $65.0K | — | 10-Q |